Status:
UNKNOWN
Avatrombopaq In Patients With Cirrhosis
Lead Sponsor:
Hvidovre University Hospital
Conditions:
Thrombocytopenia; Drugs
Cirrhosis, Liver
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Thrombocytopenia is a frequent issue in patients with cirrhosis undergoing various types of procedures (e.g. liver biopsy, endoscopy and minor surgical interventions). Thrombocytopenia \< 50\*10\^9/L ...
Eligibility Criteria
Inclusion
- Age: \>17 years and ≤80 years
- ASA I-III
- Patients who read, understood and signed informed consent.
- Patients with a diagnosis of cirrhosis
- Thrombocytopenia \<50\*109
- The patient is scheduled for one of the following procedures: Transjugular Adjusted Liver Biopsy (TJALB), gastroscopy or percutan paracentesis of ascites in the following month.
Exclusion
- Patients who do not speak and understand Danish.
- Patients who cannot cooperate within the trial.
- Patients who did not sign an informed consent regardless of the cause.
- Active drug abuse - to the discretion of the investigator.
- Thrombocytes \>50\*10\^9
- Patients with hereditary trombolic diseases (e.g. Factor V Leiden, antithrombin deficiency, protein S and C deficiency, prothrombin G202110A mutation).
- INR \> 1,7
- Ongoing infection verified by blood culture, clinical examination, and acute phase reactants (e.g. CRP)
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04845659
Start Date
June 1 2021
End Date
June 1 2022
Last Update
April 15 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.